“CDC: Antibiotic Overuse Can Be Lethal” – Wall Street Journal, 4 March 2014

According to a report by the CDC, the overuse of antibiotics used to treat patients is spurring the formation of superbugs. While treatments vary between hospitals, some doctors prescribe their patients three times the amount of antibiotics that doctors in other hospitals prescribe, for comparable diseases.

The constant misuse has rendered many antibiotics ineffective and caused the rapid development of superbugs. Misuse can also make patients susceptible to other infections, like Clostridium difficile, or C. difficile, a bacterial infection.

The CDC’s report gathered information from hospitals and patients from 2010 and 2011. The report projected that reducing antibiotic use by 30% would lower C. difficile infections by 26%. Almost 250,000 patients contract C. difficile in the hospital, which can bring on sepsis and death.

A very powerful antibiotic that is often overused is vancomycin, which is prescribed for MRSA, a strain of Staph infection. In a study, over 20% of patients who were treated with intravenous vancomycin for MRSA never had MRSA.

The government is pushing to half the amount of C. difficile infections in five years. Doing so would prevent 20,000 deaths, 150,000 hospitalizations and cut $2 billion dollars from health-care expenses.

Obama also addressed this situation in his budget proposal for 2015, which contains $30 million to study and pinpoint strains of resistant bacteria, and promote communication between communities about outbreaks and remedies.

April 12, 2014

Fluid Management Systems

Copyright 2014   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar

“Drug Makers’ Push into Injectables Could Ease Shortages” – Wall Street Journal, 26 March 2013

Healthcare and drug companies are looking to join a market largely held by hospitals: injectable drugs, a $7 billion industry that often experiences shortages.

Drug mogul Becton Dickinson (BD), for example, plans on introducing 20-30 new injectable medicines to the US over the next few years, some of which have been in short supply. International drug companies are also seizing the market. Jordan-based Hikma Pharmaceuticals will launch 5-10 products in the next few years, also introducing a few of which have been scarce.

Companies like BD are attracted to this market because of the supply issue; and while sterilizing injectable drugs can prove difficult, the payoff is big: almost one billion vials  are sold each year. However, companies might have to wait for the long-run, as producing sterile medicines can be expensive with low profits. Many companies left the market due to the cost, leaving some drugs to just one manufacturer. In addition, manufacturing problems, supply constraints and government investigation of manufacturing plants have pushed many drug firms to abandon facilities or slow down production.

What resulted was an even larger shortage in 2011: 183, as opposed to 23 five years earlier. According to the FDA, the shortages fell to 84 in 2012, partly because Pfizer began manufacturing limited cancer injectables and some plants, which were previously shut down, reopened.

Yet, in order to turn a profit, many companies are looking into raising prices by 10%. This would greatly affect hospitals and their drug buyers, who will most likely fight the increases. In order to cut costs and availability, drug companies should consider  producing and selling drugs in multi-dose vials. Fluid Management Systems, Inc. has the technology to manage and monitor injectable drug inventories in multi-dose vials.

Conceived, Developed and Written by Dr. Subodh Das and Tara Mahadevan

April 10, 2013

Fluid Management Systems

Copyright 2013   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar